Transcript: Dementia and Brain Health with JuneBrain, Crdl and U The Mind
This is the transcript for the Rethinking Aging Club Podcast episode recorded June 25, 2026.
Episode Title: Dementia and Brain Health with JuneBrain, Crdl and U The Mind
Recorded: June 25, 2026 / Published June 30, 2026
Guests:
Samantha Scott, Founder and CEO, JuneBrain
Ger Schuivens, Managing Director, Crdl
Mohammed Abouelsoud, Founder and CEO, U: The Mind Company – NeuroEdge, Tensor and Axis
Co-hosts:
Linda Sherman, Managing Editor Boomer Tech Talk, Rethinking Aging Club podcasts founder and executive producer
Ray Gordon, architect, urban planner, futurist, former Pratt Institute grad school professor and avid science reader
Debbie Howard, caregiver advocate, co-founder, Tokyo-based AgeTech platform Living Best.
Show Notes: Dementia and Brain Health with JuneBrain, Crdl and U The Mind
Linda Sherman 00:02
Welcome to the Rethinking Aging Club show. I am Linda Sherman. Each week we host presentations and discussion with special guest experts on an important topic in the field of rethinking aging. We’ll be introducing this week’s co-hosts and guests during the show. We’re happy you’ve joined us.
Today is June 25, 2026. June is Alzheimer’s and Brain Awareness Month, and our theme today is dementia and brain health.
Dementia is a recurring theme in both our Rethinking Aging Club podcasts and our News for the Ages by Rethinking Aging Club podcast.
Along with the professionals who listen to our podcast, we aim to help people 40-plus understand the best ideas, products, research, and conversations in aging, longevity, caregiving, and AgeTech before they are in crisis, so they can make smarter choices for themselves, their parents, and their future.
We ask that our speakers explain any technical language or acronyms they use today. We have three great guests for you today: Samantha Scott, PhD, founder and CEO of JuneBrain; Ger Schuivens, managing director of Crdl, and Mo Abouelsoud, founder and CEO of U: The Mind Company.
Nearly every family will be touched by dementia. Today, more than 55 million people worldwide are living with dementia, making it one of the greatest health and caregiving challenges of our time. That number is projected to reach nearly 140 million by 2050.
There is reason for hope. Scientists now believe that up to 45% of dementia cases could potentially be delayed or prevented through healthier lifestyles that we talk about on the show all the time and better management of known risk factors.
Innovation is accelerating. New therapies, AI-powered tools, digital technologies, and caregiver support solutions are transforming what’s possible for people living with dementia for the families who care for them. Our guests today are part of that exciting movement.
I want to introduce my two co-hosts, and then Debbie will take us through some statistics further on dementia and Alzheimer’s, and then Debbie will be introducing our first two guests.
First, allow me to introduce my co-host, Ray Gordon. Ray is an architect, urban planner, futurist, and prior graduate school professor at both Pratt Institute and NYU. Ray is a regular reporter on our News for the Ages by Rethinking Aging Club and brings a unique perspective to scientific aging-related topics.
Ray Gordon 03:28
Linda Sherman is the founder and executive producer of the News for the Ages podcast and the Rethinking Aging Club podcast, a participant in the AgeTech Collaborative from AARP. She is managing editor of Boomer Tech Talk, home of the club’s podcasts.
Linda previously served as CEO and CMO for multinational subsidiaries in Japan and now serves as chief longevity officer for the LA-based Miracle of the Sea. She helps people understand the best research products and conversations in aging, longevity, caregiving, and AgeTech.
Linda is also a role model for healthy longevity, staying physically fit while embracing aging with curiosity, purpose, and community.
Linda Sherman 04:11
Thank you. Ray Gordon.
Debbie Howard is a marketing and communications strategist with over 40 years of experience, including decades of work in Japan. She co-founded the Tokyo-based AgeTech platform Living Best, which uses consumer insights to guide innovation and go-to-market execution. She is also a caregiver-friendly workplace strategist and author of two books on caregiving. Through both Living Best and her company Aging Matters International, she participates in the AgeTech Collaborative from AARP.
Debbie Howard 04:52
Thank you, Linda. Here are the seven facts that I would like to share with you about dementia and Alzheimer’s, in recognition of June as Alzheimer’s and Brain Awareness Month.
Dementia is not one disease; it’s an umbrella term for conditions that affect memory, thinking, and behavior. There are more than 100 different diseases and conditions that can cause dementia, making diagnosis and treatment challenging.
Alzheimer’s disease accounts for about 60 to 70% of all cases. Alzheimer’s is progressive; it gradually damages brain cells and affects memory, reasoning, and daily function. While newer therapies can slow progression for some people, there is still no cure.
As Linda mentioned, 45% of dementia cases could potentially be delayed or prevented by addressing modifiable risk factors throughout life. Early diagnosis matters. Recognizing symptoms early gives family more time for planning, treatment options, support services, and participation in clinical trials.
Family caregivers carry much of the burden. More than 12 million Americans provide nearly 20 billion hours of unpaid dementia care each year, valued at approximately $446 billion.
Finally, dementia affects the whole family. Beyond memory loss, the disease often changes relationships, daily routines, finances, and emotional well-being for everyone involved.
Our first guest today is Dr. Samantha Scott, founder and CEO of JuneBrain, a startup developing a telehealth eye scanning system. JuneBrain is a portfolio company of the AgeTech Collaborative from AARP, and it was a graduate of its accelerator cohort for winter 2026.
Dr. Scott’s background combines her personal insight and experience with managing a neurological disorder with expertise in neuroimaging and biomedical engineering as well. This gives her a unique perspective on improving patient care. Dr. Scott completed a neuroimaging postdoc at the NIH National Institutes of Health. She earned her PhD in biomedical engineering from USC and holds a BS in biomechanical engineering from Stanford.
Dr. Samantha Scott has given us permission to call her Sam, so I’m going to introduce you that way, Sam. We are so excited to hear more about JuneBrain.
Sam Scott 07:39
Thank you very much. It’s great to be here. I appreciate the invitation, Debbie, Linda. I’m happy to share an overview of JuneBrain.
So, I started the company around nine years ago now. It’s based in Baltimore, Maryland, and the goal is really to make eye imaging more accessible to the neurology community, and I know at first it sounds a little weird. What does one have to do with the other?
But what we’re learning now, and it’s becoming clinical practice, is that the retina, or the back of the eye, can be used as a non-invasive potential biomarker of diseases like MS and Alzheimer’s.
I founded the company the same year that I was diagnosed with a nervous system disorder by my eye doctor; that was after about five years of bouncing between neurologists.
So, what my team has done now is to create a wearable form of retinal imaging; it’s called OCT, or optical coherence tomography, and what it does is take very high-resolution pictures of the back of your eye, including the structure in the eye, the vasculature, and that can be used to understand neurodegenerative disease.
Debbie Howard 08:52
Thanks so much, Sam, for your overview. Can you tell us a little bit about how this, like practically, works on a daily basis, like when I go to the eye doctor, I actually have macular degeneration already, and I’m genetically in line for glaucoma as well.
So I have a lot of things done at the eye doctor, as you can imagine, and I have for 10 years, and they have all these big opto machines. Tell us how this works into a routine in a regular doctor’s office, like what I’m doing, because I want that extra measurement you’re talking about.
Sam Scott 09:27
Yeah, that’s a great question. So, with the machines that you’re talking about, the typical OCT machines that you’ll find in an eye clinic are usually large; they’re on a table. A lot of times, they’re in their own kind of back room. They usually call it a retina scan, and the way it’s currently used is for people who are high risk for disease.
So, you mentioned your own history, Debbie, so even patients who are at risk of advanced disease. So, one is understanding, identifying disease as early as possible, retina disease. And then in people who have already been diagnosed, monitoring and tracking, so you can change treatments as needed to delay the progression of their disease.
But usually these machines are only accessible in those specialty eye clinics. What we’re trying to do is expand it outside of eye care, so taking these machines into neurology clinics, which are now using retinal biomarkers to understand neuro disease, or even one of our biggest visions is that these devices can be placed in a grocery store or pharmacy, where patients can regularly check their eyes, and that information can be used to understand their risk for eye or brain disease.
Debbie Howard 10:44
So I really love that vision, Sam, of adding this to places that will be easily accessible by the population. Can you tell us a little bit more about when this will be in the market?
Sam Scott 10:58
Yes, so we’re still pre-FDA approval. So our goal is to submit everything. We’ve been working on this for nine years. Again, we are 90% there. We have to submit our clinical study results; the final design of our commercial product to the FDA.
And then our goal is to go fully to market by the end of next year. And our first goal is to roll this out to eye clinics as well as neurology settings, but for us we also have AI on the back end that makes the device more accessible, so it automatically analyzes the images, so you don’t have to rely on hiring trained retinal photographers to analyze the data; it can really go anywhere that’s needed.
Debbie Howard 11:42
Okay, that’s great. Linda and Ray and Mo and Ger, may I ask if you have any questions for Sam?
Ray Gordon 11:50
Yes, this is Ray. Thank you. I have a question regarding the use of that data. If I go to my eye doctor and they do all these scans and photography of the retina, they keep it in their database so that every year I can compare what happened previously to the conditions that occur currently.
So, if this is going to be available all over the place, like in optometrist offices, places in pharmacies, and things of that sort, how do you coordinate that information, and how do I, as a consumer, have access to that data so I can compare one to the other?
Let’s say I go to one city and get it checked out, and six months later I go to a pharmacy in a different location.
Sam Scott 12:32
Yes, that is a great problem. It’s one of the biggest challenges around our whole model.
So, one way that we’re tackling that with our first-generation system is not removing the primary doctor from the loop. So with our first generation, it will primarily be used in people who have been diagnosed with the disease or who are currently seeing an eye doctor, for example, and are at risk of disease, so in that way doctor can write a prescription or an order, write an order for a patient to have an OCT scan done, and then they will be the ones to review the reports that come out of our system.
And that will include them being able to compare today’s results with results from six months ago. If the patient were to use our device in one place and then a second time in another place, that data can still go to their same doctor, so for the first version we’re keeping it as simple as possible.
Ray Gordon 13:28
And it will be accessible to those who may not even have an issue right away but may be potentially on the way. So, in other words, it seems like this would be a great tool to catch things very early.
Sam Scott 13:43
Yes, yep, that’s right. On the research side, it’s really fascinating. So, with Alzheimer’s specifically, amyloid-beta and tau, those are really the defining proteins of Alzheimer’s in the brain, and we know now that it also shows up in the retina.
So, for Alzheimer’s, there’s a few things that can be tracked in the retina. One is how the layers of the retina-it’s like a seven-layer, eight-layer cake—you can track how those layers are changing, if there’s thinning, which could mean cell death, which reflects what’s going on in the brain, or accumulation of amyloid.
So those are things that can be monitored from any place, so especially for patients who may not even have a primary ophthalmologist, for example, being able to go into an optical retail store and now have an OCT exam done, that store can now flag them as, “Oh, we see something in your retina that may be putting you at high risk.”
Even just being able to refer people out or triage people into a more specialized clinic makes a huge difference versus patients who may never know what’s going on, or at least not until symptoms emerge
Ray Gordon 14:58
So there will be a method for a consumer to say, “Hey, I just want to go check my eyes out and go get one of these scans,” as opposed to having to have a prescription from a doctor, because some people do not have a primary ophthalmologist available to them. Is that correct?
Sam Scott 15:14
Yes, that’s right. So one group we’ve heard from quite a bit are the optical retailers. So these are all just name brands, but not necessarily working with us. LensCrafters, Target Optical-you know, you go and you buy glasses.
What they’re now trying to do is move into the Oculumic space, which is being able to use the eye to understand neuro- and systemic disease. So they’re trying to find tools that allow people to come into their stores, buy glasses, and also be screened for, you know, look at their risk profile for a disease.
So, even if they can’t be treated at that store, it’s a way to offer that screening service to a much broader population.
Linda Sherman 15:58
I didn’t even realize there was a company called Target Optical, so obviously it’s Target and good for them; that’s exciting. And what would it cost to the consumer, hypothetically, to walk into a Target Optical and request this test?
Sam Scott 16:17
So we expect our device to be covered by insurance, so it will be based on the patient’s insurance. We have some stores that are also looking at out-of-pocket costs, so for example, a lot of times an optometry clinic will charge $50 for a retina scan, but our main push is to have Medicare, Medicaid coverage, as well as private insured coverage. They already cover retina scans, so we just need to make sure that that is the case in other settings, like a pharmacy or a neurology clinic.
Linda Sherman 16:54
And these retail optical stores do take insurance.
Sam Scott 17:00
Yes, many of them do. They have different models. Some stores, they do not work on an insurance-based model. They charge out-of-pocket fees, but the vast majority do rely on insurance to have as large a customer base as possible. So, for us, it’s very important because accessibility is what we’re here for, so even being able to move into more underserved communities, it’s important to us that there is coverage.
Linda Sherman 17:29
Excellent! Debbie.
Debbie Howard 17:30
That is excellent. Thank you for the question, Linda. You know, Sam, I love what you’re doing, and I love what you’re saying about this screening becoming more available to everyone. It is a really, really important part of our moving forward with prevention and monitoring and everything else. So, thank you for everything you’re doing.
Linda Sherman 17:52
If I did not have any insurance and I wanted to go into a retail optical establishment, what do you think it would cost me?
Sam Scott 18:04
It’s hard to say. The best I can go off of is current rates for OCT exams, and that can be $50. I’ve seen $35, so I would go with $50 or less, but it really depends on how the store prices it.
Linda Sherman 18:21
Well, that’s certainly accessible. That’s great. Thank you.
Debbie Howard 18:25
It sure is. Yeah, that’s great, Sam. Thank you so much, Linda.
Our next guest is Ger Schuivens, a Dutch international business leader with over 40 years of experience in strategic marketing, sales, business development, and executive management across both B2B and B2C markets.
Throughout his career, he has held senior leadership positions within organizations including Bose, Harte Hanks Europe, and Norton St. Gobain, building a reputation for driving growth, innovation, and operational excellence.
Today as Managing Director of Crdl, Ger leads the company’s international expansion and mission to improve human connection in care through meaningful technology-enabled experiences. If you visit crdl.com, C R D L dot com, and check out the additional visual links we have left for you in the show notes. You’ll be able to see what Ger is about to tell us about seeing is believing, and a picture is worth 1000 words, as I always like to say.
Take it away, Ger.
Ger Schuivens 19:40
Debbie, thank you very much. It’s a long time ago that I have heard so many nice words being said about me, so thank you for the invitation, and thank you for the red carpet that you rolled out here.
Yeah, Crdl is a Dutch invention; it’s a Dutch device, instrument, I should say to be exact, and is used almost at the other end of what Sam was just talking about.
When Sam talks about early diagnosis, prevention, early detection, we are almost at the other side of the dementia spectrum, which also is part of life, which is also part of the disease, but it is primarily used at the stage when people cannot communicate anymore, when they typically reside in a care home, and when they have lost the majority of their communication capabilities.
And that’s a very, very sad situation that, from a clinical point of view, one can’t really change or modify, but we have taken it as our task to make it very easy and very simple to make for a human connection by using that instrument so that even when words are not available anymore or cannot be understood and exchanged anymore, that by this instrument and by two persons sitting opposite each other and touching each other on the skin that they can have wonderful moments of enjoyment of wandering of connection.
I really invite you, as Debbie said, I can’t explain well enough in words how wonderful the instrument is, but many of our clients bring that wonderful experience forward in social media posts, and let the world enjoy what is really happening there. So, thank you for that, and thank you for allowing me to introduce Crdl.
Debbie Howard 21:53
And I just want to say, for everyone, it’s a gorgeous piece of art as well.
Ger Schuivens 21:59
Yeah, it is a gorgeous piece of art. It is actually developed by two graduated architects. They happened to study together at the Rietveld Academy in Amsterdam, and then afterwards they created a design studio together, and whilst they were managing that design studio, they were also active as volunteers in two different care homes, and given the inquisitive mind that they had, and the fact that they, you know, architects always want to come up with solutions in form and in material, and they asked the care personnel, Where are your limitations? Where is it that you reach your border and that you can’t connect with your residents anymore?
And that’s when they said, “Well, when they can’t communicate, we can give them all the basic care and service in terms of the physical care, but on a human level, if we can’t connect with them anymore, they become socially isolated.”
And that triggered Dennis and Jack, the two architects that triggered them to start thinking about how could we come up with something that makes it very easy to apply and can connect the person with advanced dementia who cannot communicate anymore, and anybody else on the other side. Could be a caregiver, it could be a partner, it could be a child or a grandchild, could be any family member, but it only takes a little bit of time and a little bit of each other touching and the instrument to go for that wonderful experience.
Debbie Howard 23:38
Thank you so much. And so, yeah, I love having seen Crdl, and it’s beautiful and tactile and wooden. It’s a little bit bigger than a football, for those of you who are listening, a US football, I should say, and a little flatter and more attractive.
But tell us a little bit more, Ger, about the wood and the material. It’s also got some laser etching or something that’s very attractive. And tell us about how two people use the Crdl, because that’s a really interesting story in and of itself.
Ger Schuivens 24:10
Thank you, Debbie. Yeah, so the design, so it is made out of a massive chunk of wood, and it’s either walnut or ash olive. Ash olive is an ash type that has a nicer, more attractive appeal to it. So, those are the two color variations that we have, and we work it into the oval form of, as you said, an American football.
And then we excavate everything on the inside to create space for all the electronics. So on the outside, you don’t really know what it is and how it works, which is part of the intriguing engagement, and on the inside, you’ve got all the electronics: a loudspeaker, two types of computers.
And with that material, so there are then two opposing pieces of touch material that you can touch with your hand. And only when you touch each other, when the two persons touching each other, Crdl starts to play and starts to make sounds. And I happen to have a Crdl here, and I just want to give you an impression of how it sounds. Putting it a bit louder.
And these sounds, they differ by the type of touch, so that’s another level of engagement. So you either hold somebody’s hand or you tap on the hand, or you caress the hand, moving left to right, or you can tickle it. So the different types of touch result in different sounds, and that’s really what makes it very interesting and very enjoyable, and this is the real uniqueness.
It can be done not only by the caregiver or the family member, but you can hand over that control, that autonomy, also to the person with dementia. You can invite them and say, “You can touch me, and then you have control over the sounds.” And when they realize that, and there is a-we call it Choppanish-there is a piece of piano music in there, and especially if they have been playing piano earlier in their life, and they feel that just by touching another person they can play piano again. It’s like a wonder is happening at the same time.
Debbie Howard 26:46
That’s so interesting, Ger. And I really, really loving this innovation. Tell us a little bit about.. I know you’ve sold through organizations, and the examples you’ve given us are through assisted living. You’re also selling to individuals; is that correct?
Ger Schuivens 27:04
Yeah, any individual who would want to have Crdl can buy it from us or from our distributor. In the US and in Canada, we work with Eugeria, who is a specialized distributor on dementia equipment or dementia solutions for both care homes and for private individuals.
Typically, Crdl is purchased by care homes and then used in the memory care section, where they can use it, I would say, about 10 times a day. That’s about the golden standard, or the golden rule that we give them. And then if you are able to do that, then the cost per interaction is less than $1.
But you can, of course, buy the instrument for interaction with your partner or with your mother, and you can use it at your home. I just don’t see it being used 10 times a day, so the economics work a little bit different in a private situation, but of course people can buy it.
Debbie Howard 28:05
May I ask how much it is?
Ger Schuivens 28:07
So, the price for a care home is about $9,500, but you can rent or lease it for $250 a month, and that, as I said, comes down to less than $1 per interaction.
Debbie Howard 28:21
I see, so individuals can rent it that way as well.
Mo Abouelsoud 28:26
Yes, they can.
Debbie Howard 28:27
Okay, that’s super interesting. Linda, Ray, Samantha, Mo, do you have questions for Ger?
Linda Sherman 28:33
The chain of people that can be touching each other and affect the sounds coming out of Crdl is fascinating. Can you explain a little bit more about how that works?
Ger Schuivens 28:50
Yeah, thank you for the question. Yeah, the chain of people we have tried a number of times to break our record in the chain connection. So you can daily chain the number of people making the connection. And our record until now has been 200 and it’s not-we think it’s not a technical limitation or a system limitation, but it’s more the patience of the 200 or 300 or whatever number of people, because they need to connect with each other. And they need to have the patience to hold each other’s hands.
So it works that we send off a five-volt current through making the connection, and what we then also register is how the natural resistance of the body changes as a result of the touch. So we have a natural resistance value in our body system, and if you are being touched by another person, that resistance value changes, and that indication is forwarded from one pole of the Crdl to the other pole of the cradle.
And it goes with the speed of electricity, so it’s literally instantaneous that it arrives at the other pole and then produces the sound that is a result of the changing touch.
Linda Sherman 30:14
Wow, thank you so much. Ray
Ray Gordon 30:16
Yes, so in other words, if you have a different number of people touching it or touching it in different way, the sound that is emitted is different. Is that correct?
Ger Schuivens 30:26
That’s correct. Yeah, so within the system we have defined five different types of sound, five different types of touch: holding is one, tapping, tickling, squeezing, gently pushing. Those are all different types of resistance value, and they’re all predefined within the sound library.
And Crdl comes with 15 different sound libraries, varying from nature to some music pieces, the sea, farm animals, city environment, so you have all different types of sound stages, sound libraries so that they also help people, because that’s the purpose-to reactivate their memory.
So, when we sit across them, the typical question that we would ask is, What do you hear, and what are you thinking of? So, we don’t label the sounds. We don’t say, Do you hear the birds or the ducks? But we ask the person to find out what they connect to, and sometimes it’s only one syllable, sometimes it’s only one little memory piece, but it goes back to what they remember of their life before they were 24 or 25 because these sounds and this recognition is stored in a different part of the brain, and by rehearing it, by repeating it to them, that’s what activates the memory.
Ray Gordon 31:54
How do you select the portion of the library you want to use? For instance, let’s say, a person grew up on a farm, and I want them to hear animals more than other kinds of sounds.
Ger Schuivens 32:05
Yeah, yeah, very good question. So there is a button on the Crdl where you can switch one sound library to the other. And we’ve also created an easier solution, which we call Motion Menu, where you just activate Motion Menu. And by tilting the Crdl, you then move forwards or backwards in the 15 libraries. So it’s very simple to operate. You just tilt and then move from one library to the other.
Ray Gordon 32:36
Is there a possibility of having that tie into some kind of a mobile app so you can actually see that in a control panel
Ger Schuivens 32:43
To tie it into a mobile app, we deliberately stayed away from making any external connection as far as Crdl is concerned, because not all locations, not all care locations, are equally equipped in connection or in Wi-Fi installations or in Bluetooth installations. And we didn’t want to create another level of complexity, so it works either on a button-based or just moving along from one library to another, and the moving along happens within 30 seconds.
Ray Gordon 33:16
Is there a limit to how long the battery is? I’m assuming it’s battery-operated. How do you charge?
Ger Schuivens 33:22
It comes with a charger and with a charging cable. It has a USB-C port. You can hook up the Crdl to a computer to a PC and view the entire directory, including all the control files, and you can charge it in less than four hours, and it will remain available and active for 16 hours of full operation.
Ray Gordon 33:49
Great. And do you have the ability to upgrade the library in the future?
Ger Schuivens 33:55
Even better, it’s not only an upgrade. Yes, you can download new sounds that we develop and then download them from the portal and register them on your cradle. That’s one step, but you can create your own soundscapes, so if somebody comes from a particular area where they have particular special sound elements from their youth, you just record those as an MP3, MP4, or a WAV file, and you can register them through the application that we have and then store them on Crdl.
Ray Gordon 34:30
Great, thank you.
Debbie Howard 34:31
It just really sounds amazing. I wonder if Mo or Sam have a question for Ger before we move on to Mo?
Sam Scott 34:38
No, no, none for me, but it sounds amazing. Thank you for sharing. I’m actually on your website right now.
Mo Abouelsoud 34:46
Yeah, I’m fully in line with the idea that the body is electric and responds to natural signals. So, I love what you’re doing.
Ger Schuivens 34:56
Thank you. Thank you. Our domain is enhancing quality of life; that’s what our mission and our goal is for persons with dementia, and we like to give them as good a life quality that everybody deserves.
Debbie Howard 35:12
That’s great. Thank you so much, everyone. We’re going to move on now to our third and final guest today. Linda, would you take over again?
Linda Sherman 35:21
Certainly. And I did want to share that Stacy Eisenberg in our audience said, “I’ve seen Crdl at a conference in Austin last year and was very impressed.” I’m jealous, Stacy, because I’ve been dying to get my hands on a Crdl. And I can imagine, I know this is not the use for today-but a rich person’s party, where you bring out a cradle, and wouldn’t that be awesome? So it has multiple possibilities.
So I am so pleased to be able to introduce Mohammed Abouelsoud. He is the founder and CEO of U: The Mind Company, a Columbus, Ohio-based neurotechnology innovator focused on advancing noninvasive neuromodulation solutions.
A computational neuroscientist and entrepreneur, Abouelsoud has spent the past eight years researching the intersection of neuroscience, human performance, and precision medicine. Inspired by his personal journey with bipolar disorder, he founded the company to develop technologies that support brain health and neurological care.
His work focuses on precision neurostimulation for conditions such as Parkinson’s disease and Alzheimer’s disease, while exploring its potential to enhance cognitive performance, resilience, and healthy aging worldwide. Mo Abouelsoud, please, thank you.
Mo Abouelsoud 37:04
Thank you so much, everybody. And yes, we’re super excited about our work and our company. We’re partnering with researchers with the Mayo Clinic, Cleveland Clinic, and MIT; Harvard University, University of Michigan, a lot of high-quality neurologists and physicians on our team advancing our work.
What we do is we have a device that looks like a headband, like a basketball headband, and it sends very gentle electrical signals into the brain, into the front part of the brain, the frontal lobe, and these signals they help tune the hemispheres of the brain together, the left and right hemispheres of the brain, as well as increasing the activity region of the brain called the frontal cortex.
Frontal cortex in the brain helps with decision-making, focus, and memory. So, basically, the headband sends these electrical signals to increase focus, decision-making, and memory in Alzheimer’s disease patients, as well as patients in mild cognitive impairment and dementia disorders as a whole.
We completed a clinical study. We have hospital approval. We got approval by the neurologist. We showed an increase of 580% connectivity and activation in the hippocampus, which is the memory region of the brain.
That means before stimulation, the patients were unable to recall their names or the names of their family members. After 12 weeks of stimulation 15 minutes a day, they put this headband on, they plug it in, turns on 15 minutes a day, after 12 weeks, they were able to recall the names of their family members. they were able to control their bowel movements and urination, eat more as well as engage in light conversations with the people around them. These were mild-to-moderate Alzheimer’s disease patients.
Very big deal. Very excited. Publish this clinical study in a peer-reviewed book chapter journal. Super excited about the work ahead. Then this is our company. We can share a lot more about what we do. Thank you.
Linda Sherman 39:23
Thank you so much, Mo. I really appreciate that. What country were the patients in?
Mo Abouelsoud 39:30
They were in the Middle East, so we have patients all over the globe. We have over 300 patients all over the globe with a wide variety of diseases using the technology. Actually, every single continent we do have patients on every single continent, except for Antarctica, of course.
Linda Sherman 39:47
Great, your work in dementia is certainly exciting. Can you talk more about how that works, how the technology works to help with Alzheimer’s and dementia?
Mo Abouelsoud 40:01
Yeah, so with Alzheimer’s and dementia as a whole, there is degeneration of neurons across the brain, meaning if you look at the brain of a patient with dementia, there is less brain, there’s literally less matter, there’s less. And because there’s less matter, there’s less firing, less activation, less signaling, and so what we do is we reintroduce signals.
So, if you imagine a brain like a big highway system patient with dementia they have roads blocked and collapsed and potholes everywhere. And so what we do is we come in, we add pavement and rebuild the highways again. We reconstruct the highways by sending instead of internal signals, we create the external signals.
So essentially we send an external pulse, an external wave, an external current, an external frequency. We send it through the forehead; we send it into the frontal lobe, which is the main part of the brain associated with decision-making. We send it into that region, and we rebuild the highway slowly over time. We rebuild the highway. We tell the frontal lobe, fire, fire, fire, activate, activate, activate, activate.
If you ever seen those stimulators that they sell on TV, where you put these pads on your stomach and they flex your abs, it’s like ab flexor, flex, flex, flex, flex, flex. We do the same exact conceptually, except this time we’re flexing the brain. We’re telling the brain flex, flex, flex, flex, flex, and when we tell the brain flex, flex, flex, flex, flex, the brain grows stronger, stronger, stronger, stronger, because it has to get bigger. It has to increase the neurogenesis.
It has to increase the myelination, the white matter, the gray matter, the connectivity has to, because all of a sudden it’s realizing it needs to be on more, you know what I’m saying. So that’s the concept of the device: these set electrical signals into the front part of the head to activate that part of the brain.
Debbie Howard 42:12
That’s so helpful, Mo. I really can see how that works now. And what a great innovation. It’s amazing to think that we could actually do something about the problem, so I really, really appreciate everything that you all are doing there.
Linda Sherman 42:30
Mo, at the top of your website, uthemind dot company, we see this sentence: “Whether you’re optimizing your mind or managing a neurological condition, we have a path for you.”
And then you describe NeuroEdge as a consumer-grade wellness device built on our neurostimulation platform, designed for everyday focus, clarity, and cognitive performance at home.
In your FAQs, you have: What is the difference between NeuroEdge and your clinical devices? NeuroEdge uses lower-power, consumer-grade waveforms designed for home use; Tensor for Parkinson’s and Axis for Alzheimer’s use higher-power, higher-resolution waveform modulation with multi-pathway targeting for deeper brain structures. That level of precision is required for pathological neurological conditions and is physician-monitored only.
Could you just say a word about that?
Mo Abouelsoud 43:40
Yeah, so this technology, this class of technology, is called electrical stimulation. This technology can be applied to a wide variety of diseases and healthy people. In fact, we just onboarded a group of boxers, UFC fighters, and professional soccer players, and then the Olympian to use the technology to enhance their athletic abilities.
Every single human being on planet Earth, when their frontal lobe is activated properly, they can make better decisions, better decisions on the soccer field, better decisions in the workplace, better decisions in their marriage, better decisions with how they eat, better decisions overall. Frontal lobe equals decision-making. When you enhance frontal lobe, you enhance decision-making.
Every human needs better decision-making: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, depression, healthy humans. So this technology can be applied to a wide variety of people.
Now, each brain needs different signal frequencies. Okay, some brains need a faster frequency, while another brain needs a slower frequency. In fact, our new model will have personalized signal frequencies, meaning if you want to send a signal to help wake you up, we can send that. We can send you a signal in the brain to help slow you down. Go to sleep.
This technology to be transparent and something we’re interested in. We’re going to be running studies with the proper approvals can be applied to all mammal brains, including dogs. Okay, because this technology helps increase activation in certain brain areas.
So the hypothesis is we can use this technology to get dogs to focus better, to calm down, to be able to be more emotionally resilient, respond to stress better, because they have a bigger brain. We increase the volume of the brain, we increase the size of the brain, and when you increase the size of the brain, the brain can make better decisions.
Debbie Howard 45:49
Interesting, Mo, thank you so much for explaining that.
Linda Sherman 45:54
I did have one follow-up question on that. What do you call the class of products, brain electrical stimulation?
Mo Abouelsoud 46:02
Yeah, transcranial electrical stimulation. In fact, there’s electrical stimulation for the spine, there’s electrical stimulation for your muscles, there’s electrical stimulation for the eyes. This is coming, a new thing, new transorbital stimulation. It’s called just electrical stimulation. It’s the idea that the body is electric, and so we can stimulate the body through external electrical devices. Transcranial electrical stimulation is the brain class, but electrical stimulation is the biggest class. So, think about it like that, electrical stimulation.
Linda Sherman 46:36
That’s so helpful. Thank you, Mo. Ray.
Ray Gordon 46:39
I have a couple of questions. Can it be available for individual use? If that’s the case, is there any issue with how often you would use this, how long you use it, what kind of depth, the length of the sessions you need to see these improvements to happen?
Mo Abouelsoud 46:55
Yes, so the device is available for sale. We have a version of the device that’s lower power, not medical grade, available to sale right now. You can buy it, we can send it to you within four days for healthy humans, cognitive enhancement, and it’s used for 15 minutes a day.
Now, some people, they find the stimulation to be very unique, so they started off with five minutes, and then they worked their way up to 15 minutes, but 15 minutes a day, once a day, in fact, more is not better, more is actually worse. Okay, too much stimulation is like overrunning. When you overrun, you lead to injury. You don’t need to overrun; all you need to do is run a few miles, walk a few miles, get your body moving, so there’s something called overstimulation, biphasic dose response, and so it’s just used 15 minutes a day, once a day.
Now, patients with different diseases, we personalize it, because sometimes they have to use it for longer, okay, or sometimes they have to use it for shorter, but that comes from our clinical team, we make the decision as to why the simulation needs to be longer for shorter, but generally it’s 15 minutes a day.
Ray Gordon 48:06
So, if I was to purchase this, I could get some guidance from your company as to what I want to use it for. How many minutes a day? How long should I use it? Things of that sort.
Mo Abouelsoud 48:17
Yes, your health, I don’t know your specific situation, but if you were to buy just for cognitive enhancement, you would use it for 15 minutes a day. You would use it for decision-making. You use it to enhance your focus. You use it to enhance your communication. Again, anything related to frontal lobe, anything related to frontal lobe, we help enhance.
Linda Sherman 48:37
I think Ray is asking, what type of support do you provide? You said you need to tune it and that kind of thing. So, what kind of service do you have?
Mo Abouelsoud 48:48
No, no, the device is pre-tuned. It’s easy, it’s plug-and-play. It’s straight out the package. It’s plug-and-play. And you have access to brain health coaches who are certified, who are able to tell you exactly how to use it, and they meet with you once every three weeks to be able to get your updates, because the device-the effects compound, you know. Week four of the device is much less significant than week eight. When you get to week eight, the effects are much more powerful, so the effects compound over time, grow again, again, again, again, again.
Ray Gordon 49:23
That’s great. And also, what is the cost of this device?
Mo Abouelsoud 49:26
350 USD for the non-medical-grade version
Ray Gordon 49:31
Like, it’s rechargeable and lasts a decent amount of time?
Mo Abouelsoud 49:35
Yeah, so it’s plug and play. We also have a new alpha, another version coming out in a few months, that will also be able to record brain activity, not only re-stimulate the brain, but record the brain and tune the pulses. But yes, this new device is very, very durable, and obviously we offer back guarantees and repairs and everything. If something happens, if it falls, it breaks, or something, but it’s very durable. We have these for a while.
Ray Gordon 50:01
Thank you very much.
Linda Sherman 50:03
Stacy Eisenberg in the audience is asking: “With dementia, do the patients feel the current? I’m curious about how dementia patients react.”
Mo Abouelsoud 50:16
Yeah, so you can feel kind of like the like a little prick, prick, prick, prick on your forehead, pick, pick, pick, pick. If you ever use a 10s unit, it’s kind of like that. Oh, we’re building out a new unit now that’s adjustable, so if the prick is too much, you can lower it a little bit.
But yeah, you can feel it on your skin, but you don’t feel anything inside your brain, and so it’s all on the outside of the brain, you know what I mean, but yes, you can feel it. In fact, if you don’t feel it, that’s when you contact us, because then something’s wrong with the device. You need to feel it, because that’s what we’re doing; we’re stimulating the brain, you know.
Linda Sherman 50:54
Great. Okay. Thank you so much. We really appreciate that very understandable explanation, and Stacy answered in the audience that she’s used attends, and this is a field where there are other players, but I think you’re making some very interesting advancements, and you’ve been doing this quite a while, so it’s been in the field since when?
Mo Abouelsoud 51:22
This technology has been studied for over three decades. There are thousands and thousands of studies on this technology. Hundreds of thousands of people have used it.
What we’ve done, we started our company eight years ago; we’ve optimized it, but this field, electrical brain stimulation has been around for decades—tons and tons and tons of safety data.
Linda Sherman 51:43
Excellent. Thank you so much. And thank you so much to all of our speakers for being here. We really appreciate you, and thank you so much to everyone.
Thank you for joining us today. This is Linda Sherman, founder of the Rethinking Aging Club. We appreciate your supporting the Rethinking Aging Club podcast by subscribing to our channel. See you next time.